Last $7.40 USD
Change Today -0.01 / -0.13%
Volume 49.3K
ATNM On Other Exchanges
As of 8:04 PM 07/9/14 All times are local (Market data is delayed by at least 15 minutes).

actinium pharmaceuticals inc (ATNM) Key Developments

M. Yair Levy Joins Actinium Pharmaceuticals, Inc.'s Iomab-B Scientific Advisory Board

Actinium Pharmaceuticals, Inc. announced the addition of M. Yair Levy, MD of Baylor to its Scientific Advisory Board (SAB) for Iomab(TM)-B. Iomab(TM)-B. Dr. Levy is Medical Director, Hematologic Malignancy Clinical Research of the Texas Oncology-Baylor Charles A. Sammons Cancer Center in Dallas, Texas. He was previously on the Faculty at Sidney Kimmel Comprehensive Care Center at Johns Hopkins.

Actinium Pharmaceuticals, Inc.(AMEX:ATNM) added to Russell 2000 Index

Actinium Pharmaceuticals, Inc. will be added to the Russell 2000 Index.

Actinium Pharmaceuticals, Inc.(AMEX:ATNM) added to Russell 3000 Index

Actinium Pharmaceuticals, Inc. will be added to the Russell 3000 Index.

Actinium Pharmaceuticals, Inc. Announces Establishment of Iomab-B Scientific Advisory Board

Actinium Pharmaceuticals, Inc. announced the establishment of its Scientific Advisory Board (SAB) for Iomab(TM)-B comprised of several preeminent clinicians in the fields of oncology, hematology, and bone marrow transplant. Combining the wealth of clinical, strategic, and scientific experience in cancer drug development, the Scientific Advisory Board is well suited to support the company's development strategy for the advancement of Iomab(TM)-B, the Company's lead radioimmunotherapy asset, in a Phase 3 trial to potentially address the significant unmet medical need for older patients with acute myeloid leukemia (AML) and well as in other cancer indications. The inaugural members of Actinium's SAB for Iomab(TM)-B include the following renowned clinicians in hematology, oncology and bone marrow transplant. Listed in alphabetical order, the members are: Sergio A. Giralt, MDMemorial Sloan Kettering Cancer Center, New York, NY. Dr. Giralt is Chief, Adult Bone Marrow Transplant Service; Acting Chief, Myeloma Service, and a board-certified hematologist/oncologist whose clinical practice and research focus on stem cell transplantation for patients with blood disorders. Dr. Giralt and his colleagues pioneered the use of reduced-intensity conditioning regimens for older or more debilitated patients with blood cancers, and are currently using and studying T cell depletion techniques to dramatically reduce the risk of graft-versus-host disease, a serious complication of donor stem cell transplantation. Most recently, Dr. Giralt was Deputy Chair of the Department of Stem Cell Transplantation and Cellular Therapies at the University of Texas MD Anderson Cancer Center. He is also the past chair of the steering committee of the Blood and Marrow Transplant Clinical Trials Network, a federally funded group that defines the research agenda for stem cell transplantation in the United States. Hillard M. Lazarus, MDUniversity Hospitals Case Medical Center, Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH. Dr. Lazarus is a Professor of Medicine, Director of Novel Cell Therapy, Disease Team Leader of Cellular Therapy Integrated Services, and is board-certified in Internal Medicine, Medical Oncology and Hematology. He received his MD from the University of Rochester School of Medicine prior to Residency at the Case Western Reserve University/University Hospitals Case Medical Center. Additional Fellowships include those sponsored by the Leukemia Society of America and the American Cancer Society. Peter A. McSweeney, MDColorado Blood Cancer Institute at Presbyterian/St. Luke's, Rocky Mountain Blood and Marrow Transplant Program, University of Colorado, Denver, CO. McSweeney is Clinical Associate Professor of Medicine and is board-certified in Internal Medicine, Hematology and Hematopathology. He earned his MD at the University of Otago Medical School in Dunedin, New Zealand. He completed his Residency and Fellowships at Wellington Public Hospital in New Zealand. In the US, he completed fellowships in clinical hematology, hematopathology and oncology at Fred Hutchinson Cancer Research Center (FHCRC), and then worked in clinical research at FHCRC and became an Assistant Professor at the University of Washington School of Medicine. Dr. McSweeney was the clinical director and laboratory medical director at the University of Colorado's Blood and Marrow Transplant Program. He has been published numerous times and won many awards for his work in blood and marrow transplantation. John M. Pagel, MD, PhDFred Hutchinson Cancer Research Center, Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, WA. Dr. Pagel is an Associate Professor of Medical Oncology and Associate Member in the Clinical Research Division of FHCRC. He received a PhD in microbiology and molecular genetics from the University of California, Irvine and his MD (magna cum laude) from Boston University School of Medicine.

Actinium Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-26-2014 11:00 AM

Actinium Pharmaceuticals, Inc. Presents at BIO International Convention, Jun-26-2014 11:00 AM. Venue: San Diego Convention Center, San Diego, California, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATNM:US $7.40 USD -0.01

ATNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATNM.
View Industry Companies

Industry Analysis


Industry Average

Valuation ATNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINIUM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at